Melanomas y carcinomas basocelulares en un paciente con enfermedad de Parkinson
Clinical Features, Pathophysiology, and Treatment of Levodopa-Induced Dyskinesias in Parkinson's Disease
PDF) Continuous levodopa for advanced Parkinson's disease
PDF) Levodopa-induced dyskinesias in Parkinson's disease: Emerging treatments
Frontiers | Molecular Mechanisms and Therapeutic Strategies for Levodopa-Induced Dyskinesia in Parkinson's Disease: A Perspective Through Preclinical and Clinical Evidence
Fyn Knock-Down Prevents Levodopa-Induced Dyskinesia in a Mouse Model of Parkinson's Disease | eNeuro
The relationship between the distinct ratios of benserazide and carbidopa to levodopa and motor complications in Parkinson's disease: A retrospective cohort study - ScienceDirect
Evaluation of Levodopa Dose and Magnitude of Dopamine Depletion as Risk Factors for Levodopa-Induced Dyskinesia in a Rat Model of Parkinson's Disease | Journal of Pharmacology and Experimental Therapeutics
Levodopa-Induced Dyskinesia in Parkinson's Disease
PDF) Apomorphine and levodopa infusion for motor fluctuations and dyskinesia in advanced Parkinson disease
Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap - The Lancet Neurology
Time course for AIM scores following levodopa. Rats were treated daily... | Download Scientific Diagram
Profile of levodopa/carbidopa intestinal gel and its potential in the | JPRLS
PDF) Levodopa-induced plasticity: A double-edged sword in Parkinson's disease
Biomolecules | Free Full-Text | Treatment Options for Motor and Non-Motor Symptoms of Parkinson's Disease | HTML
Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs | Nature Reviews Drug Discovery
Brain Sciences | Free Full-Text | Transcriptome Sequencing Reveal That Rno-Rsf1_0012 Participates in Levodopa-Induced Dyskinesia in Parkinson’s Disease Rats via Binding to Rno-mir-298-5p | HTML
Levodopa-Induced Dyskinesia in Parkinson Disease: Current and Evolvin…
PDF) A Computational Model of Levodopa-Induced Toxicity in Substantia Nigra Pars Compacta in Parkinson's Disease
PDF) Dyskinesia and brain-derived neurotrophic factor levels after long-term levodopa and nicotinic receptor agonist treatments in female mice with near-total unilateral dopaminergic denervation
Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson's disease: focus on levodopa/carbidopa/entacapone
Current Knowledge on the Background, Pathophysiology and Treatment of Levodopa-Induced Dyskinesia— Literature Review
Frontiers | The Human Experience with Intravenous Levodopa
